ID   EMRE_ECOLI              Reviewed;         110 AA.
AC   P23895; Q2MBN8;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 1.
DT   15-FEB-2017, entry version 141.
DE   RecName: Full=Multidrug transporter EmrE;
DE   AltName: Full=Efflux-multidrug resistance protein EmrE;
DE   AltName: Full=Ethidium resistance protein;
DE   AltName: Full=Methyl viologen resistance protein C;
GN   Name=emrE; Synonyms=eb, mvrC; OrderedLocusNames=b0543, JW0531;
OS   Escherichia coli (strain K12).
OC   Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1936950; DOI=10.1016/0378-1097(91)90338-B;
RA   Purewal A.S.;
RT   "Nucleotide sequence of the ethidium efflux gene from Escherichia
RT   coli.";
RL   FEMS Microbiol. Lett. 66:229-231(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1320256; DOI=10.1093/nar/20.12.3159;
RA   Morimyo M., Hongo E., Hama-Inaba H., Machida I.;
RT   "Cloning and characterization of the mvrC gene of Escherichia coli K-
RT   12 which confers resistance against methyl viologen toxicity.";
RL   Nucleic Acids Res. 20:3159-3165(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RA   Chung E., Allen E., Araujo R., Aparicio A.M., Davis K., Duncan M.,
RA   Federspiel N., Hyman R., Kalman S., Komp C., Kurdi O., Lew H., Lin D.,
RA   Namath A., Oefner P., Roberts D., Schramm S., Davis R.W.;
RT   "Sequence of minutes 4-25 of Escherichia coli.";
RL   Submitted (JAN-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J.,
RA   Mau B., Shao Y.;
RT   "The complete genome sequence of Escherichia coli K-12.";
RL   Science 277:1453-1462(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   "Highly accurate genome sequences of Escherichia coli K-12 strains
RT   MG1655 and W3110.";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [6]
RP   FUNCTION, AND KINETIC PARAMETERS.
RC   STRAIN=K12 / JM109 / ATCC 53323;
RX   PubMed=7896833; DOI=10.1074/jbc.270.12.6856;
RA   Yerushalmi H., Lebendiker M., Schuldiner S.;
RT   "EmrE, an Escherichia coli 12-kDa multidrug transporter, exchanges
RT   toxic cations and H+ and is soluble in organic solvents.";
RL   J. Biol. Chem. 270:6856-6863(1995).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=9050242;
RA   Schuldiner S., Lebendiker M., Yerushalmi H.;
RT   "EmrE, the smallest ion-coupled transporter, provides a unique
RT   paradigm for structure-function studies.";
RL   J. Exp. Biol. 200:335-341(1997).
RN   [8]
RP   FUNCTION, PH DEPENDENCE, AND MUTAGENESIS OF GLU-14.
RC   STRAIN=K12 / JM109 / ATCC 53323;
RX   PubMed=10681497; DOI=10.1074/jbc.275.8.5264;
RA   Yerushalmi H., Schuldiner S.;
RT   "An essential glutamyl residue in EmrE, a multidrug antiporter from
RT   Escherichia coli.";
RL   J. Biol. Chem. 275:5264-5269(2000).
RN   [9]
RP   FUNCTION.
RX   PubMed=11574548; DOI=10.1074/jbc.M108231200;
RA   Ninio S., Rotem D., Schuldiner S.;
RT   "Functional analysis of novel multidrug transporters from human
RT   pathogens.";
RL   J. Biol. Chem. 276:48250-48256(2001).
RN   [10]
RP   REVIEW.
RX   PubMed=11443233;
RA   Schuldiner S., Granot D., Mordoch S.S., Ninio S., Rotem D., Soskin M.,
RA   Tate C.G., Yerushalmi H.;
RT   "Small is mighty: EmrE, a multidrug transporter as an experimental
RT   paradigm.";
RL   News Physiol. Sci. 16:130-134(2001).
RN   [11]
RP   MUTAGENESIS OF LEU-7; ALA-10; ILE-11; GLU-14; GLY-17 AND THR-18.
RX   PubMed=12590142; DOI=10.1074/jbc.M213120200;
RA   Gutman N., Steiner-Mordoch S., Schuldiner S.;
RT   "An amino acid cluster around the essential Glu-14 is part of the
RT   substrate- and proton-binding domain of EmrE, a multidrug transporter
RT   from Escherichia coli.";
RL   J. Biol. Chem. 278:16082-16087(2003).
RN   [12]
RP   TOPOLOGY.
RX   PubMed=15044024; DOI=10.1016/S0014-5793(04)00240-6;
RA   Ninio S., Elbaz Y., Schuldiner S.;
RT   "The membrane topology of EmrE - a small multidrug transporter from
RT   Escherichia coli.";
RL   FEBS Lett. 562:193-196(2004).
RN   [13]
RP   SUBUNIT.
RX   PubMed=15111102; DOI=10.1016/S0014-5793(04)00228-5;
RA   Ubarretxena-Belandia I., Tate C.G.;
RT   "New insights into the structure and oligomeric state of the bacterial
RT   multidrug transporter EmrE: an unusual asymmetric homo-dimer.";
RL   FEBS Lett. 564:234-238(2004).
RN   [14]
RP   FUNCTION.
RX   PubMed=15371426; DOI=10.1074/jbc.M408187200;
RA   Rotem D., Schuldiner S.;
RT   "EmrE, a multidrug transporter from Escherichia coli, transports
RT   monovalent and divalent substrates with the same stoichiometry.";
RL   J. Biol. Chem. 279:48787-48793(2004).
RN   [15]
RP   SUBUNIT.
RX   PubMed=14755055; DOI=10.1073/pnas.0306533101;
RA   Elbaz Y., Steiner-Mordoch S., Danieli T., Schuldiner S.;
RT   "In vitro synthesis of fully functional EmrE, a multidrug transporter,
RT   and study of its oligomeric state.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:1519-1524(2004).
RN   [16]
RP   MUTAGENESIS OF TRP-63, AND SUBUNIT.
RX   PubMed=15882076; DOI=10.1021/bi050356t;
RA   Elbaz Y., Tayer N., Steinfels E., Steiner-Mordoch S., Schuldiner S.;
RT   "Substrate-induced tryptophan fluorescence changes in EmrE, the
RT   smallest ion-coupled multidrug transporter.";
RL   Biochemistry 44:7369-7377(2005).
RN   [17]
RP   SUBSTRATE-BINDING CAVITY.
RX   PubMed=16049002; DOI=10.1074/jbc.M504910200;
RA   Sharoni M., Steiner-Mordoch S., Schuldiner S.;
RT   "Exploring the binding domain of EmrE, the smallest multidrug
RT   transporter.";
RL   J. Biol. Chem. 280:32849-32855(2005).
RN   [18]
RP   TOPOLOGY [LARGE SCALE ANALYSIS].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=15919996; DOI=10.1126/science.1109730;
RA   Daley D.O., Rapp M., Granseth E., Melen K., Drew D., von Heijne G.;
RT   "Global topology analysis of the Escherichia coli inner membrane
RT   proteome.";
RL   Science 308:1321-1323(2005).
RN   [19]
RP   MUTAGENESIS OF TYR-4; TYR-6; TYR-40; TYR-53 AND TYR-60.
RX   PubMed=16672221; DOI=10.1074/jbc.M602088200;
RA   Rotem D., Steiner-Mordoch S., Schuldiner S.;
RT   "Identification of tyrosine residues critical for the function of an
RT   ion-coupled multidrug transporter.";
RL   J. Biol. Chem. 281:18715-18722(2006).
RN   [20]
RP   SUBUNIT.
RX   PubMed=17003034; DOI=10.1074/jbc.M607186200;
RA   Soskine M., Mark S., Tayer N., Mizrachi R., Schuldiner S.;
RT   "On parallel and antiparallel topology of a homodimeric multidrug
RT   transporter.";
RL   J. Biol. Chem. 281:36205-36212(2006).
RN   [21]
RP   STRUCTURE BY NMR.
RX   PubMed=9688273; DOI=10.1046/j.1432-1327.1998.2540610.x;
RA   Schwaiger M., Lebendiker M., Yerushalmi H., Coles M., Groeger A.,
RA   Schwarz C., Schuldiner S., Kessler H.;
RT   "NMR investigation of the multidrug transporter EmrE, an integral
RT   membrane protein.";
RL   Eur. J. Biochem. 254:610-619(1998).
RN   [22]
RP   STRUCTURE BY ELECTRON MICROSCOPY (7.5 ANGSTROMS) IN COMPLEX WITH THE
RP   DRUG TPP(+).
RX   PubMed=14633977; DOI=10.1093/emboj/cdg611;
RA   Ubarretxena-Belandia I., Baldwin J.M., Schuldiner S., Tate C.G.;
RT   "Three-dimensional structure of the bacterial multidrug transporter
RT   EmrE shows it is an asymmetric homodimer.";
RL   EMBO J. 22:6175-6181(2003).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (3.8 ANGSTROMS).
RX   PubMed=14970332; DOI=10.1073/pnas.0400137101;
RA   Ma C., Chang G.;
RT   "Structure of the multidrug resistance efflux transporter EmrE from
RT   Escherichia coli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:2852-2857(2004).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (3.7 ANGSTROMS) IN COMPLEX WITH THE DRUG TPP(+),
RP   AND SUBUNIT.
RX   PubMed=16373573; DOI=10.1126/science.1119776;
RA   Pornillos O., Chen Y.-J., Chen A.P., Chang G.;
RT   "X-ray structure of the EmrE multidrug transporter in complex with a
RT   substrate.";
RL   Science 310:1950-1953(2005).
RN   [25]
RP   ERRATUM, AND RETRACTION.
RX   PubMed=17185584; DOI=10.1126/science.314.5807.1875b;
RA   Chang G., Roth C.B., Reyes C.L., Pornillos O., Chen Y.J., Chen A.P.;
RL   Science 314:1875-1875(2006).
RN   [26]
RP   STRUCTURE BY ELECTRON MICROSCOPY (7.5 ANGSTROMS), AND 3D-STRUCTURE
RP   MODELING.
RX   PubMed=17005200; DOI=10.1016/j.jmb.2006.08.072;
RA   Fleishman S.J., Harrington S.E., Enosh A., Halperin D., Tate C.G.,
RA   Ben-Tal N.;
RT   "Quasi-symmetry in the cryo-EM structure of EmrE provides the key to
RT   modeling its transmembrane domain.";
RL   J. Mol. Biol. 364:54-67(2006).
CC   -!- FUNCTION: Multidrug transporter that expels positively charged
CC       hydrophobic drugs across the inner membrane of E.coli., thereby
CC       conferring resistance to a wide range of toxic compounds. The drug
CC       efflux is coupled to an influx of protons. Is involved in the
CC       resistance of E.coli cells to methyl viologen, ethidium bromide
CC       and acriflavine. Is also able to transport tetraphenylphosphonium
CC       (TPP(+)) and benzalkonium. {ECO:0000269|PubMed:10681497,
CC       ECO:0000269|PubMed:11574548, ECO:0000269|PubMed:15371426,
CC       ECO:0000269|PubMed:7896833}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=247 uM for methyl viologen {ECO:0000269|PubMed:7896833};
CC         Vmax=1572 nmol/min/mg enzyme with methyl viologen as substrate
CC         {ECO:0000269|PubMed:7896833};
CC       pH dependence:
CC         Optimum pH is 8-8.5. Transport activity occurs from pH 7.5 to 9.
CC         {ECO:0000269|PubMed:10681497};
CC   -!- SUBUNIT: Homodimer; parallel. May also form dimer of homodimers.
CC       Binds substrate at the dimerization interface.
CC       {ECO:0000269|PubMed:14755055, ECO:0000269|PubMed:15111102,
CC       ECO:0000269|PubMed:15882076, ECO:0000269|PubMed:16373573,
CC       ECO:0000269|PubMed:17003034}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane
CC       protein.
CC   -!- MISCELLANEOUS: Encoded by the cryptic lambdoid prophage DLP12.
CC   -!- SIMILARITY: Belongs to the small multidrug resistance (SMR)
CC       protein family. {ECO:0000305}.
CC   -!- CAUTION: EM structures show an asymmetric dimer with the monomers
CC       in an antiparallel orientation, in contradiction with biochemical
CC       data and cross-linking studies, which demonstrated a parallel
CC       arrangement. Until now, EmrE with a parallel orientation is the
CC       only one to be shown to be fully functional. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Z11877; CAA77936.1; -; Genomic_DNA.
DR   EMBL; M62732; AAA24190.1; -; Genomic_DNA.
DR   EMBL; U82598; AAB40740.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC73644.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE76318.1; -; Genomic_DNA.
DR   PIR; JN0329; JN0329.
DR   RefSeq; NP_415075.1; NC_000913.3.
DR   RefSeq; WP_001070439.1; NZ_LN832404.1.
DR   PDB; 2I68; EM; -; A/B=1-110.
DR   PDB; 3B5D; X-ray; 3.80 A; A/B=1-110.
DR   PDB; 3B61; X-ray; 4.50 A; A/B/C/D/E/F/G/H=1-110.
DR   PDB; 3B62; X-ray; 4.40 A; A/B/C/D=1-110.
DR   PDBsum; 2I68; -.
DR   PDBsum; 3B5D; -.
DR   PDBsum; 3B61; -.
DR   PDBsum; 3B62; -.
DR   ProteinModelPortal; P23895; -.
DR   SMR; P23895; -.
DR   BioGrid; 4259366; 101.
DR   DIP; DIP-9505N; -.
DR   STRING; 511145.b0543; -.
DR   TCDB; 2.A.7.1.3; the drug/metabolite transporter (dmt) superfamily.
DR   PaxDb; P23895; -.
DR   PRIDE; P23895; -.
DR   DNASU; 948442; -.
DR   EnsemblBacteria; AAC73644; AAC73644; b0543.
DR   EnsemblBacteria; BAE76318; BAE76318; BAE76318.
DR   GeneID; 948442; -.
DR   KEGG; ecj:JW0531; -.
DR   KEGG; eco:b0543; -.
DR   PATRIC; 32116248; VBIEscCol129921_0564.
DR   EchoBASE; EB0623; -.
DR   EcoGene; EG10629; emrE.
DR   eggNOG; ENOG410814C; Bacteria.
DR   eggNOG; COG2076; LUCA.
DR   HOGENOM; HOG000268006; -.
DR   InParanoid; P23895; -.
DR   KO; K03297; -.
DR   OMA; YAIAFWM; -.
DR   PhylomeDB; P23895; -.
DR   BioCyc; EcoCyc:EMRE-MONOMER; -.
DR   BioCyc; MetaCyc:EMRE-MONOMER; -.
DR   SABIO-RK; P23895; -.
DR   EvolutionaryTrace; P23895; -.
DR   PRO; PR:P23895; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0016021; C:integral component of membrane; IDA:EcoliWiki.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:EcoCyc.
DR   GO; GO:0016020; C:membrane; IDA:EcoliWiki.
DR   GO; GO:0005886; C:plasma membrane; IDA:EcoCyc.
DR   GO; GO:0015199; F:amino-acid betaine transmembrane transporter activity; IMP:EcoCyc.
DR   GO; GO:0015297; F:antiporter activity; IDA:EcoliWiki.
DR   GO; GO:0015220; F:choline transmembrane transporter activity; IMP:EcoCyc.
DR   GO; GO:0015307; F:drug:proton antiporter activity; IDA:EcoCyc.
DR   GO; GO:0022857; F:transmembrane transporter activity; IDA:CACAO.
DR   GO; GO:0006974; P:cellular response to DNA damage stimulus; IEP:EcoliWiki.
DR   GO; GO:0015871; P:choline transport; IMP:EcoCyc.
DR   GO; GO:0031460; P:glycine betaine transport; IMP:EcoCyc.
DR   GO; GO:0042493; P:response to drug; IMP:EcoliWiki.
DR   GO; GO:0006970; P:response to osmotic stress; IMP:EcoCyc.
DR   GO; GO:0006810; P:transport; IDA:EcoliWiki.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IMP:EcoliWiki.
DR   InterPro; IPR000390; Small_multidrug_res.
DR   Pfam; PF00893; Multi_Drug_Res; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Antiport; Cell inner membrane; Cell membrane;
KW   Complete proteome; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN         1    110       Multidrug transporter EmrE.
FT                                /FTId=PRO_0000108074.
FT   TOPO_DOM      1      3       Cytoplasmic.
FT   TRANSMEM      4     21       Helical; Name=1.
FT   TOPO_DOM     22     33       Periplasmic.
FT   TRANSMEM     34     52       Helical; Name=2.
FT   TOPO_DOM     53     57       Cytoplasmic.
FT   TRANSMEM     58     81       Helical; Name=3.
FT   TOPO_DOM     82     84       Periplasmic.
FT   TRANSMEM     85    105       Helical; Name=4.
FT   TOPO_DOM    106    110       Cytoplasmic.
FT   SITE          4      4       Required for proper coupling between the
FT                                substrate transport and the proton
FT                                gradient.
FT   SITE         14     14       Essential for translocation and for
FT                                substrate and proton binding.
FT   SITE         40     40       Involved in substrate binding.
FT   SITE         60     60       Involved in substrate binding.
FT   SITE         63     63       Involved in substrate binding.
FT   MUTAGEN       4      4       Y->C: Still binds substrate. No transport
FT                                activity in the presence of a proton
FT                                gradient, but still transports substrate
FT                                in the absence of a proton gradient.
FT                                Resistance to toxicants is abolished.
FT                                {ECO:0000269|PubMed:16672221}.
FT   MUTAGEN       4      4       Y->F,W: No effect on resistance to
FT                                toxicants. {ECO:0000269|PubMed:16672221}.
FT   MUTAGEN       6      6       Y->C,F,L: No effect on resistance to
FT                                toxicants. {ECO:0000269|PubMed:16672221}.
FT   MUTAGEN       7      7       L->C: No substrate binding. Resistance to
FT                                toxicants is abolished.
FT                                {ECO:0000269|PubMed:12590142}.
FT   MUTAGEN      10     10       A->C: Still binds substrate, with lower
FT                                affinity. Resistance to toxicants is
FT                                abolished. {ECO:0000269|PubMed:12590142}.
FT   MUTAGEN      11     11       I->C: Still binds substrate, with lower
FT                                affinity. Resistance to toxicants is
FT                                abolished. {ECO:0000269|PubMed:12590142}.
FT   MUTAGEN      14     14       E->C: No substrate binding. No transport
FT                                activity. Resistance to toxicants is
FT                                abolished. {ECO:0000269|PubMed:10681497,
FT                                ECO:0000269|PubMed:12590142}.
FT   MUTAGEN      14     14       E->D: Still binds substrate. No transport
FT                                activity in the presence of a proton
FT                                gradient, but still transports substrate
FT                                in the absence of a proton gradient.
FT                                Resistance to toxicants is abolished.
FT                                {ECO:0000269|PubMed:10681497,
FT                                ECO:0000269|PubMed:12590142}.
FT   MUTAGEN      17     17       G->C: No substrate binding. Resistance to
FT                                toxicants is abolished.
FT                                {ECO:0000269|PubMed:12590142}.
FT   MUTAGEN      18     18       T->C: Still binds substrate, with lower
FT                                affinity. Resistance to toxicants is
FT                                abolished. {ECO:0000269|PubMed:12590142}.
FT   MUTAGEN      40     40       Y->C,F,L,M,S,T,V: Modifies substrate
FT                                specificity.
FT                                {ECO:0000269|PubMed:16672221}.
FT   MUTAGEN      53     53       Y->C: No effect on resistance to
FT                                toxicants. {ECO:0000269|PubMed:16672221}.
FT   MUTAGEN      60     60       Y->C,F: Still binds substrate, with lower
FT                                affinity. Resistance to toxicants is
FT                                abolished. {ECO:0000269|PubMed:16672221}.
FT   MUTAGEN      63     63       W->C,Y: No transport activity. Resistance
FT                                to toxicants is abolished.
FT                                {ECO:0000269|PubMed:15882076}.
FT   MUTAGEN      63     63       W->F: Still binds substrate, with two-
FT                                fold reduction in substrate affinity.
FT                                Resistance to toxicants is abolished.
FT                                {ECO:0000269|PubMed:15882076}.
FT   HELIX         5     20       {ECO:0000244|PDB:2I68}.
FT   HELIX        35     51       {ECO:0000244|PDB:2I68}.
FT   HELIX        59     79       {ECO:0000244|PDB:2I68}.
FT   HELIX        88    103       {ECO:0000244|PDB:2I68}.
SQ   SEQUENCE   110 AA;  11958 MW;  775153FC47D6AE3D CRC64;
     MNPYIYLGGA ILAEVIGTTL MKFSEGFTRL WPSVGTIICY CASFWLLAQT LAYIPTGIAY
     AIWSGVGIVL ISLLSWGFFG QRLDLPAIIG MMLICAGVLI INLLSRSTPH
//
